The market size of Japan in single-use bioprocessing is estimated to be USD 1.24 Billion in 2025 and is estimated to grow at a CAGR of 16.70% between 2026 and 2035 to USD 1.45 billion and then rise to about USD 5.82 billion in 2026 and 2035 respectively.
Japan Single Use Bioprocessing Market Revenue and Trends
The Japan market of single use bioprocessing offers disposable systems such as bioreactors, mixers, tubing, connectors, sensors, bags, filters, and chromatography columns to manufacture biologics, vaccines, cell/gene therapies, and monoclonal antibodies with flexibility, less risk of contamination, and fast turnaround that are not offered by stainless steel systems. Japan's single-use bioprocessing market is expanding at a fast rate, as the domestic production of biologics and biosimilars increases, the investment in the production of cell/gene therapies grows, the safety of the products must be strictly controlled, and the high-performance polymers, integrated sensor technologies, and automation-compatible disposable platforms become a part of the biopharmaceutical ecosystems.
.png)
What are the Factors That Have a Significant Contribution to the Growth of the Japan single use bioprocessing market?
The increased biopharmaceutical manufacturing capacity, which resulted because of the approvals of new biologics by PMDA, the growing age population, which demands high-tech therapies, and government efforts to enhance domestic supply chains after the COVID crisis have created higher demand for single-use bioprocessing products. With the growth of Japanese pharma and biotech companies in facilities and flexible manufacturing to small batch size and multi-product manufacturing, more companies will turn to disposable systems to ease the load on the cleaning validation and speed up time-to-market.
The latest technology has brought about such innovations as gamma-sterilized high-volume single-use bioreactors, enhanced single-use sensors of real-time PAT (process analytical technology), connector systems free of leaks, and end-to-end disposable process trains, which improve scalability, reliability, and compliance. Additional issues are the greater interest in supply chain resiliency, AMED funding more regenerative medicine production, the growth of the CDMO industry to serve international customers, and regulatory encouragement of new production technologies and biopharma sustainability.
Segment Insight
By Product Type
Single-use bioreactors and fermenters have by far the largest share of the Japan single use bioprocessing market as of 2025 by product, whereas production of monoclonal antibodies, vaccines, and cell therapies has a strong demand alongside cross-contamination risk and is being improved by scalability, favored by large numbers of bioprocess engineers and bioprocess manufacturers, which has prompted further innovation in stir-tank, wave-rocking, and high density perfusion bioreactors.
By Distribution Channel
The greatest market share is in direct sales to pharmaceutical companies and CDMOs that are considered key sources of acquisition of customized single-use systems, technical validation support, and connection with automation platforms. The channels have become a choice for sourcing single use bioprocessing technologies, as they offer professional expertise in designing processes, regulatory compliance (PMDA), supply chain reliability, and even post-sale engineering services.
Report Scope
Feature of the Report | Details |
Market Size in 2026 | USD 1.45 billion |
Projected Market Size in 2035 | USD 5.82 billion |
Market Size in 2025 | USD 1.24 Billion |
CAGR Growth Rate | 16.70% CAGR |
Base Year | 2025 |
Forecast Period | 2026-2035 |
Key Segment | By Product Type, Application, Workflow, End User, Type of Cell and Region |
Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Recent Developments
In June 2025: The new cleanroom capacity added to Sartorius Japan local single-use manufacturing plant to produce large volumes of bioreactor bags and sensor assemblies in-house increased the reliability of supply and customization to domestic cell therapy and vaccine manufacturers.
List of the prominent players in the Japan Single-Use Bioprocessing Market:
Thermo Fisher Scientific Japan
Sartorius Japan
Merck KGaA (Japan operations)
Cytiva (Danaher Japan)
Eppendorf Japan
Asahi Kasei Corporation
SATAKE MultiMix Corporation
Pall Corporation (Japan)
Repligen Corporation (Japan)
ZACROS Co. Ltd.
Boehringer Ingelheim Japan
REPROCELL Inc.
Others
The Japan Single-Use Bioprocessing Market is segmented as follows:
By Product Type
Single-Use Bioreactors (SUBs)
o Stirred-Tank Bioreactors
o Wave-Induced Bioreactors
o Bubble Column Bioreactors
o Others
Media Bags and Containers
o 2D Bags
o 3D Bags
o Bioprocess Containers
o Others
Filtration Assemblies
o Tangential Flow Filtration (TFF)
o Depth Filters
o Sterile Filtration Capsules
o Membrane Adsorbers
Disposable Mixers
o Magnetic Mixers
o Rocking Platform Mixers
o Others
Tubing and Connectors
o Transfer Tubing
o Aseptic Connectors
o Sample Bags
Other Products
o Sampling Systems
o Sensors
o Accessories
By Application
Cell Culture
Filtration
Purification
Storage
Mixing
Other Applications
By Workflow
Upstream Bioprocessing
Downstream Bioprocessing
Process Development
By End User
Biopharmaceutical Manufacturers
Contract Development and Manufacturing Organizations (CDMOs)
Academic and Research Institutions
Other End Users
By Type of Cell
Mammalian Cells
Microbial Cells
Other Cell Types
